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Danielle M. Zerr,1,3 Michael Boeckh,2,4 Colleen Delaney,1,4 Paul J. Martin,2,4 Hu Xie,4
Amanda L. Adler,3 Meei-Li Huang,4 Lawrence Corey,4 Wendy M. Leisenring4Human herpesvirus 6 (HHV-6) reactivation has been associated with acute graft-versus-host-disease
(aGVHD), cytomegalovirus reactivation, and mortality after allogeneic hematopoietic cell transplantation
(HCT), but previous studies have yielded inconsistent results. We performed a large prospective study of
allogeneic HCT recipients in order to more definitively define the relationships between HHV-6 and these
important outcomes. Plasma specimens were collected prospectively from 315 allogeneic HCT recipients
and tested for HHV-6 DNA at baseline and twice weekly for 12 weeks. Cox proportional hazards models
were used to evaluate the time-dependent associations between HHV-6 reactivation and the targeted out-
comes. HHV-6 was detected in 111 of 315 patients (35%) at a median of 20 days after HCT. HHV-6 reacti-
vation was associated with subsequent cytomegalovirus reactivation (adjusted hazard ratio [aHR], 1.9; 95%
confidence interval [CI], 1.3-2.8; P5 .002). High-level HHV-6 (.1,000 HHV-6 DNA copies/mL) was associ-
ated with subsequent grades II to IV aGVHD (aHR, 2.4; 95% CI, 1.60-3.6; P\.001). High-level HHV-6 reac-
tivation was also associated with nonrelapse mortality (aHR, 2.7; 95% CI, 1.2-6.3; P 5 .02). HHV-6
reactivation was independently and quantitatively associated with increased risk of subsequent cytomegalo-
virus reactivation, aGVHD, and mortality after HCT. A randomized antiviral trial is warranted to establish
causality between HHV-6 and these endpoints and to determine if reducing HHV-6 reactivation will improve
outcome after HCT.
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graft-versus-host diseaseINTRODUCTION
Human herpesvirus 6 (HHV-6) infects 90% to
100% of individuals during early childhood [1]. After
primary infection,HHV-6 establishes a latent infection
in hematopoietic reservoirs. This latent infection can
become active in settings of severe immunosuppression,
especially hematopoietic cell transplantation (HCT).
Prior studies show that HHV-6 reactivates in approxi-
mately 40% of patients after HCT [2-4], and
reactivation has variably been associated with
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oi.org/10.1016/j.bbmt.2012.05.012(CMV) reactivation [5], acute graft-versus-host-
disease (aGVHD) [2,6,7], and increased mortality
[4,6]. Whether HHV-6 is actually causally associated
with these problems remains controversial.
We performed a large prospective study ofHHV-6
inHCT recipients in an effort to better understand the
relationships between HHV-6, CMV, aGVHD, and
mortality in these patients.MATERIALS AND METHODS
The data presented in this report were generated in
part from a prospective study designed to evaluate the
associations between HHV-6 reactivation and neuro-
psychiatric and neurocognitive outcomes [8]. The pro-
tocol was approved by the Fred Hutchinson Cancer
Research Center Institutional Review Board.
Patients
Patients of all ages undergoing allogeneic HCT
from January 2005 through August 2008 were eligible
for enrollment. Those with limited English profi-
ciency were excluded due to the frequent neuropsychi-
atric and neurocognitive assessments required for the
Figure 1. Consort diagram.
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during the pretransplantation evaluation, and 474 were
preliminarily enrolled (Figure 1). Of the 474 patients,
a total of 152 withdrew or were deemed ineligible
before contributing data, leaving 322 patients who
contributed data. Six patients with HHV-6 DNA
levels suggestive of chromosomal integration [9] (de-
termined a priori as increasing HHV-6 plasma DNA
levels during the first 2 weeks after HCT and persis-
tent levels $100 copies per/mL in $80% of subse-
quent plasma samples) were excluded from analyses.
An additional patient, who contributed only baseline
data, was also excluded. Of the 315 included patients,
nearly all (n 5 308; 98%) were followed for $4 weeks
after HCT or until death.
Clinical Care
Participation in this study had no impact on clinical
decisions, including those involving conditioning regi-
mens, type of transplantation, aGVHD prophylaxis
and treatment, or administration of antimicrobials.
There were no recipients of T cell-depleted stem cell
grafts. CMV reactivation was monitored and treated
per clinical standards of care. From the initiation of
the study through February 2007, the primary mode of
CMVscreeningwasCMVantigenemia.After this point,
plasma CMV PCR became the primary means of CMV
screening. Patients were tested weekly for evidence of
CMV reactivation through approximately day 100 after
HCT.Apre-emptive antiviral therapy approachwas fol-
lowed [10,11]. Ganciclovir was the first-line antiviral
postengraftment, and foscarnet was the second.
Study Procedures
Baseline (pre-HCT) and twice-weekly plasma
specimens were collected through day 84 post-HCT
for HHV-6 testing. A total of 6,255 specimens were
obtained (85% of planned). Patients were followed
through day 200 for mortality.
Clinical Data and Definitions
Demographic, clinical, and laboratory information
was collected from clinical records and databases.
Underlying disease was categorized as ‘‘less ad-
vanced’’ or ‘‘more advanced’’ (Table 1) [12].
Medical comorbidity was defined and categorized
using a validated scale [13].
Pretransplantation lymphopenia was assessed at
the last lymphocyte count obtained before starting
conditioning chemotherapy and was defined as a lym-
phocyte count\600 (approximate lowest quartile).
Conditioning regimens were categorized as ‘‘mye-
loablative,’’ ‘‘nonmyeloablative,’’ or ‘‘reduced inten-
sity.’’ A variety of cytoreductive regimens were used;
the most common regimens are reported in Table 1
by myeloablative category.HHV-6 reactivation was defined as any level of
plasma HHV-6 DNA.
High-level HHV-6 reactivation was defined
as$1,000 HHV-6 DNA copies/mL plasma. This level
was chosen because it is a threshold for CMV that is
commonly used to initiate use of pre-emptive antiviral
therapy. In addition, in the context of this study, it is
close to the median maximum level (873 HHV-6
copies/mL plasma).
CMV reactivation was defined as any level of
plasma CMV DNA or whole blood antigenemia.
High-level CMV reactivation was defined as
$1,000 CMV DNA copies/mL plasma or 10 cells/
high-powered field of CMV antigenemia.
Acute graft-versus-host disease (aGVHD) grades
and organ-specific types (skin, gastrointestinal, and
liver) and stages were categorized as previously de-
scribed by a single investigator (P.J.M.) blinded to
HHV-6 study results [14].
Chronic graft-versus-host disease (cGVHD) was
categorized as previously described [15].
Overall mortality was defined as mortality occur-
ring for any reason.
Nonrelapse mortality was defined as mortality oc-
curring for reasons other than relapse in patients re-
ceiving myeloablative HCT or for reasons other than
relapse or progression of underlying disease in patients
receiving nonmyeloablative HCT.
Table 1. Demographic and Clinical Characteristics of the
Cohort, Overall and Stratified by ever having HHV-6
Reactivation
Overall
(n 5 315)
n (%)
HHV-6 Reactivation
(n 5 315)
No
(n 5 204)
Yes
(n 5 111)
Age
#20 yrs 63 (20) 33 (16) 30 (27)
21-30 yrs 22 (7) 12 (6) 10 (9)
31-40 yrs 31 (10) 22 (11) 9 (8)
41-50 yrs 51 (16) 34 (17) 17 (15)
>50 yrs 148 (47) 103 (50) 45 (41)
Female sex 126 (40) 82 (40) 44 (40)
Race/ethnicity
White 257 (82) 172 (84) 85 (76)
Hispanic 10 (3) 6 (3) 4 (4)
Native American 6 (2) 3 (2) 3 (3)
Other 42 (13) 23 (11) 19 (17)
CMV donor/recipient
serostatus
Donor+/recipient+ 80 (25) 48 (24) 32 (29)
Donor+/recipient2 31 (10) 21 (10) 10 (9)
Donor2/recipient+ 92 (29) 57 (28) 35 (31)
Donor2/recipient2 112 (36) 78 (38) 34 (31)
Positive HSV serostatus 265 (85) 167 (83) 98 (88)
Medical comorbidity
Low 93 (30) 52 (26) 41 (37)
Moderate 95 (30) 68 (33) 27 (24)
High 127 (40) 84 (41) 43 (39)
More advanced
underlying disease*
174 (55) 109 (53) 65 (59)
TBI
$1,200 cGy 72 (23) 36 (17) 36 (33)
#400 cGy 127 (40) 81 (40) 46 (41)
None 116 (37) 87 (43) 29 (26)
Conditioning regimen
Myeloablative† 169 (54) 110 (54) 59 (53)
Nonmyeloablative‡ 112 (35) 79 (39) 33 (30)
Reduced intensity§ 34 (11) 15 (7) 19 (17)
HLA match
Matched related 98 (31) 74 (36) 24 (22)
Matched unrelated 142 (45) 95 (47) 47 (42)
Mismatched relatedjj 10 (3) 4 (2) 6 (5)
Mismatched unrelated¶ 65 (21) 31 (15) 34 (31)
Stem cell source
Bone marrow 61 (19) 34 (17) 27 (24)
Cord blood 21 (7) 6 (3) 15 (14)
Peripheral blood stem cell 233 (74) 164 (80) 69 (62)
HHV indicates human herpesvirus; CMV, cytomegalovirus; HSV, herpes
simplex virus; TBI, total body irradiation.
*‘‘More advanced’’ underlying disease refers to diagnoses other than
acute myeloid leukemia, acute lymphoblastic leukemia, or lymphoma
in first remission, chronic myeloid leukemia in chronic phase, and refrac-
tory anemia without excess blasts.
†Myeloablative regimens included: any regimen containing $800 cGY
TBI, any regimen containing carmustine/etoposide/cytarabine/melpha-
lan (BEAM), or any regimen containing busulfan/cyclophosphamide
with or without antithymocyte globulin. The most common regimens
included busulfan and cyclophosphamide (n 5 73), cyclophosphamide
and >1,200 cGY TBI (n 5 47), and cyclophosphamide, fludarabine,
and 1,320 cGY TBI (n 5 13).
‡The nonmyeloablative regimen was fludarabine 90 mg/m2 +/2 TBI
<300 cGY. The most common regimens included fludarabine and 200
cGY TBI (n 5 76) and fludarabine and 300 cGy TBI (n 5 9).
§All other regimens were considered reduced intensity. The most
common regimen was treosulfan and fludarabine (n 5 17).
jjAllele or antigenmismatch: 9/10 (n5 4), 6/10 (n5 1), and 5/10 (n5 5).
¶Allele or antigen mismatch: 9/10 (n 5 40), 8/10 (n 5 4), cord blood
transplantation (CBT) recipients (n 5 21) - all CBTs were mismatched,
and a subset (n 5 16) was double CBTs.
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ity were categorized as ‘‘low activity’’ (acyclovir) or
‘‘high activity’’ (foscarnet, ganciclovir, or cidofovir).
Laboratory Procedures
Individuals blinded to patients’ clinical status per-
formed PCR analyses as previously described [8]. De-
tection of 1 copy of HHV-6DNA/reaction (25 copies/
mL of plasma) was considered a positive specimen. All
HHV-6 DNA identified by PCR was typed as HHV-6
A or B [16].
Statistical Analyses
Cox proportional hazards models were used to
evaluate the impact of HHV-6 on the hazards of sub-
sequent occurrence of each of the endpoints of interest
for this study: CMV reactivation, aGVHD, cGVHD,
and mortality. Mortality was assessed through day
200, whereas CMV and aGVHD were assessed
through 100 days, and cGVHD endpoints were as-
sessed both through day 100 and 1 year. Both grades
II to IV and III to IV overall aGVHD were evaluated.
In addition, organ-specific aGVHD was examined us-
ing the stages that specifically inform overall aGVHD
grades II to IV and III to IV: stages 3 to 4 and 4 skin
subtypes and stages 1 to 4 and 2 to 4 liver and gastro-
intestinal subtypes. The number of observations was
insufficient to perform multivariable analyses of grade
IV overall aGVHD. We also evaluated a composite
endpoint of any mortality, grade II to IV aGVHD,
or any level of CMV reactivation to evaluate the im-
pact HHV-6 reactivation has on the likelihood of re-
maining alive and free of aGVHD and CMV
reactivation through 200 days after HCT. The key
risk factor of interest for all analyses was HHV-6 reac-
tivation, modeled as a time-dependent covariate and
coded as positive using 2 definitions (modeled sepa-
rately): (1) any level of detectable HHV-6 and (2)
HHV-6$1,000 copies/mL plasma. Additional covari-
ates included baseline demographic and clinical vari-
ables (Table 1). When HLA match was analyzed as
a covariate, 3 strata were used: ‘‘matched (10 of 10 al-
lele and antigen matched) related’’ versus ‘‘matched
unrelated’’ versus ‘‘mismatched related’’ plus ‘‘mis-
matched unrelated.’’ Mismatched related and mis-
matched unrelated were combined into one category
due to the small number of mismatched related cases
(n 5 10). We also evaluated pretransplantation lym-
phopenia as defined above in each of themodels. In ad-
dition, the dose of CD34-postive cells, use of
antithymocyte globulin, female donor/male recipient
status, and prior HCT were investigated in models
for aGVHD. Administration of antiviral medications
was also examined as a covariate for CMV reactivation.
As an initial variable selection step, each factor was
evaluated in a bivariable model with HHV-6 and
Table 2. Multivariable Models EvaluatingHHV-6 as a Predictor of CMVReactivation by Day 100 after HCT in Patients Seropositive
for CMV (Donor or Recipient)
Any Level CMV High-level CMV
aHR (95% CI) P Value aHR (95% CI) P Value
Models with any level HHV-6
HHV-6 reactivation 1.88 (1.26-2.82) .002 1.14 (0.61-2.13) .69
Covariates*,†,‡,§ Covariates†,‡,jj
Models with high-level HHV-6
HHV-6 reactivation 1.56 (0.96-2.54) .08 3.11 (1.52-6.36) .002
Covariates*,†,‡,§ Covariates†,‡,jj,¶
HHV-6 indicates human herpesvirus-6; CMV, cytomegalovirus; HCT, hematopoietic cell transplantation; aHR, adjusted hazard ratio; CI, confidence
interval.
Covariates included in the final multivariable models: *recipient CMV positive, †stem cell source, ‡myeloablative transplant, §pretransplantation
lymphocyte count, jjHLA match, and ¶age.
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2-sided P value was\ .20 or if its inclusion modified
the effect of HHV-6 by .10%. Once included in
a full multivariable model, in stepwise evaluation,
each factor was retained if its P value was\ .10 or if
its inclusion modified the effect of HHV-6
by .10%. Potential interactions between HHV-6
and other key variables were formally assessed when
indicated. Interaction terms between HHV-6 and
aGVHD were evaluated in mortality models. We
were unable to explore interaction between HHV-6
and stem cell source because most patients who under-
went cord blood transplantation (CBT) had HHV-6
reactivation. Instead, analyses were repeated on a co-
hort without the CBT recipients. All reported P values
are 2-sided and considered significant if P\ .05.RESULTS
Of the 315 patients included in analyses, 63 (20%)
were\21 years of age, 169 (54%) received myeloabla-
tive conditioning, and 217 (69%) received cells from
unrelated or HLA-mismatched related donors
(Table 1). The stem cell source was growth factor-
mobilized peripheral blood cells for 233 (74%), bone
marrow for 61 (19%), and cord blood for 21 (7%).
Of the 21CBT recipients, 76% received double CBTs.
HHV-6
HHV-6 was detected in 111 (35%) of the 315 pa-
tients by day-84 post-HCT. The median time to first
detection among those with reactivation was 20 days
(interquartile range [IQR], 15-28 days) after HCT.
The median duration of the first episode of HHV-6
detection, from the first positive through the last con-
secutive positive, was 4 days (IQR, 1-11 days). Theme-
dian maximum DNA level was 873 copies/mL (IQR,
175-4,580), and the HHV-6 DNA level was $1,000
copies/mL in 53 (17%). HHV-6 was detected in 16
(76%) of the 21 CBT recipients, and in all cases, the
HHV-6 DNA level was $1,000 copies/mL. All
detected HHV-6 was type B.HHV-6 and CMV
Only the patients with donor or recipient CMV
seropositive status (n5 203) were included in analyses
of CMV reactivation. The distribution of HLAmatch
categories and stem cell source among these 203 pa-
tients was similar to the overall cohort (data not
shown). Any level of CMV reactivation occurred in
128 of 203 patients (63%) who were donor or recipi-
ent CMV-seropositive. High-level CMV reactivation
(antigenemia $10 cells per high-powered field or
CMV DNA level $1,000 copies /mL) occurred in
54 (26%), and CMV disease occurred in 7 (3%). First
detection of any level of CMV reactivation occurred at
a median of 36 days (IQR, 25-53 days) after HCT. In
patients with donor or recipient CMV seropositive,
HHV-6 reactivation (any DNA level) was indepen-
dently associated with increased risk of subsequent
CMV reactivation of any level (adjusted hazard ratio
[aHR], 1.88; 95% confidence interval [CI], 1.26-
2.82; P 5 .002) but was not associated with high-
level CMV reactivation (Table 2). In contrast,
high-level HHV-6 reactivation (.1,000 copies
DNA/mL) was not significantly associated with
CMV reactivation at any level (Table 2), but it was
strongly associated with increased risk of subsequent
high-level CMV reactivation (aHR, 3.11; 95% CI,
1.52-6.36; P 5 .002). The addition of grades II to IV
or grades III to IV aGVHD to the multivariable
models of HHV-6 and CMV reactivation did not
markedly change the HR point estimates or statistical
significance forHHV-6, even though the aGVHD co-
variates were strong predictors of CMV reactivation
(data not shown). Analyses were repeated excluding
the CBT recipients, and the results were not meaning-
fully different (data not shown). The number of obser-
vations was insufficient to evaluate HHV-6
reactivation as a predictor of CMV disease. In addi-
tion, there were few patients who received ganciclovir,
foscarnet, or cidofovir early after HCT; therefore, we
were unable to evaluate the impact of these antivirals
on risk of CMV or HHV-6 reactivation or HHV-6
viral DNA levels.
Figure 2. Results from multivariable models evaluating human herpes-
virus 6 (HHV-6) reactivation as a risk factor for subsequent acute graft-
versus-host disease (aGVHD) by day 100. (A) Full cohort. (B) Excluding
cord blood recipients. Covariates included in the final multivariable
models: 1age, 2conditioning regimen, 3stem cell source, 4sex, 5underlying
disease, 6HLA match, 7cytomegalovirus (CMV) serostatus, 8CD34 dose,
9comorbidity index, and 10female donor/male recipient.
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Grade II to IV aGVHD was diagnosed in 240 pa-
tients (76%) with onset of symptoms or signs at a me-
dian of 27 days (IQR, 19-41 days) after transplantation.
Grade III to IV aGVHD was diagnosed in 50 patients
(16%) with onset of symptoms at a median of 22 days
(IQR, 12-28 days) after transplantation. Among the
patients who developed HHV-6 and subsequent
aGVHD, the interval between the first detection of
HHV-6 and onset of the first symptoms or signs of
grade II to IV aGVHD was a median of 11 days
(IQR, 5-25 days; n 5 63) and between HHV-6 and
grade III to IV aGVHD was a median of 4.5 days
(IQR, 3-7 days; n 5 12). Similar intervals were ob-
served between high-level HHV-6 and the aGVHD
outcomes (data not shown). In a multivariable model,we observed a nonsignificant but suggestive associa-
tion between HHV-6 reactivation and subsequent
grade II to IV overall aGVHD (aHR, 1.36; 95% CI,
0.99-1.88; P5 .06). The association was strengthened
when high-level HHV-6 reactivation was evaluated
(aHR, 2.39; 95% CI, 1.60-3.56; P\ .001). HHV-6 re-
activation was not, however, significantly associated
with grade III to IV overall aGVHD (Figure 2).
HHV-6 reactivation was evaluated in multivariable
models as a risk factor for organ-specific subtypes of
aGVHD: skin, gastrointestinal, and liver aGVHD.Asig-
nificant association was demonstrated between HHV-6
and stages 3 to 4 skin aGVHD (aHR, 1.71; 95% CI,
1.04-2.81;P5 .04), and the associationwas strengthened
when high-level HHV-6 reactivation was evaluated
(aHR, 2.01; 95% CI, 1.08-3.75; P 5 .03; Figure 2).
High-level HHV-6 was associated with increased risk
of both subsequent stages 1 to 4 and 2 to 4 hepatic
aGVHD (aHR, 2.34; 95% CI, 1.03-5.30; P 5 .04 and
aHR, 4.53; 95% CI, 1.10-18.68; P 5 .04, respectively;
Figure 2). High-level HHV-6 was also associated with
increased risk of subsequent stages 1 to 4 gastrointestinal
aGVHD (aHR, 1.68; 95% CI, 1.05-2.68; P 5 .03;
Figure 2).
Analyses of aGVHD excluding CBT recipients
produced similar results (Figure 2), although associa-
tions became statistically significant for any level of
HHV-6 and grades II to IV overall aGVHD as well
as for high-level HHV-6 and grades III to IV overall
aGVHD. In addition, statistical significancewas dimin-
ished for associations of high-levelHHV-6 and stages 1
to 4 hepatic aGVHD as well as for both any level and
high-level HHV-6 and stages 3 to 4 skin aGVHD.
HHV-6 and cGVHD
HHV-6 reactivation was not associated with
cGVHD by day 100 in either univariate (HR, 1.19;
95% CI, 0.84-1.69; P 5 .33) or multivariate (HR, 1.18;
95% CI, 0.82-1.71; P 5 .38) analyses. Similar results
were obtained at the 1-year time point (data not shown).
HHV-6 and Mortality
Overall, 60 of the 315 patients (19%) died by day
200 after HCT and in 40 patients (13%), the cause
of death was considered to be nonrelapse mortality.
Of the 40 patients with nonrelapse mortality, 17
(43%) had a fatal infection with (n 5 7) or without
(n 5 10) aGVHD. Other causes included multiorgan
failure (10; 25%), respiratory failure (3; 8%), cerebro-
vascular event (3; 8%), and other causes (7; 18%).
High-level HHV-6 reactivation was indepen-
dently associated with increased risk of nonrelapse
mortality (aHR, 2.70; 95% CI, 1.15-6.34; P 5 .02).
There was a suggestion that both any level of HHV-
6 reactivation and high-level HHV-6 reactivation
were associated with an increased risk of overall
Table 3. Multivariable Models Evaluating HHV-6 (Modeled as any Level and Level >1,000 Copies/mL) as a Risk Factor of the
Outcome Mortality (Evaluated as Overall Mortality and as Nonrelapse Mortality)
Overall Mortality by Day 200 Non-relapse Mortality by Day 200
aHR (95% CI) P Value aHR (95% CI) P Value
Models with any level of HHV-6
Any HHV-6 alone
Any HHV-6 1.69 (0.99-2.87) .053 1.74 (0.88-3.41) .11
Covariates*,†,‡ Covariates*,†,‡,§,jj,¶,**
Any HHV-6 with aGVHD grades II-IV
Any HHV-6 1.60 (0.93-2.75) .09 1.73 (0.87-3.42) .12
aGVHD grades II-IV 1.36 (0.71-2.58) .35 1.61 (0.72-3.62) .25
Covariates*,†,‡ Covariates*,‡,¶
Any HHV-6 with aGVHD grades III-IV
Any HHV-6 1.42 (0.82-2.45) .21 1.37 (0.70-2.70) .36
aGVHD grades III-IV 2.88 (1.61-5.14) <.001 4.39 (2.23-8.63) <.001
Covariates*,†,‡ Covariates*,‡
Models with high-level HHV-6
HHV-6 alone
HHV-6 >1,000 c/mL 1.95 (0.99-3.86) .054 2.70 (1.15-6.34) .02
Covariates*,†,‡,§,jj,¶ Covariates*,‡,§,jj,¶,††
HHV-6 with aGVHD grades II-IV
HHV-6 >1,000 c/mL 1.81 (0.90-3.62) .10 2.50 (1.04-6.03) .04
aGVHD grades II-IV 1.33 (0.69-2.57) .39 1.35 (0.59-3.09) .48
Covariates*,†,‡,§,¶ Covariates*,‡,§,jj,¶,††
HHV-6 with aGVHD grades III-IV‡‡
HHV-6 and aGVHD grades III-IV composite variable
Neither HHV-6 or aGVHD grades III-IV Reference Reference
HHV-6 >1,000 c/mL only 2.61 (1.22-5.62) .014 3.61 (1.45-8.99) .006
aGVHD grades III-IV only 4.42 (2.34-8.34) <.001 7.02 (3.35-14.7) <.001
HHV-6 >1,000 c/mL and aGVHD grades III-IV 2.50 (0.72-8.71) .15 4.36 (0.93-20.4) .06
Covariates*,†,‡,§,¶ Covariates*,‡,¶,††
HHV-6 indicates human herpesvirus-6; aHR, adjusted hazard ratio; CI, confidence interval; aGVHD, acute graft-versus-host disease.
Models were evaluated with and without aGVHD as a covariate (modeled as grade II-IVor grade III-IV) and with and without CMV reactivation as a co-
variate. CMV reactivation was not a significant predictor of mortality, and its inclusion in the model did not affect the HHV-6 point estimate or signif-
icance (data not shown).
Other covariates included in the final models: *age, †underlying disease, ‡ cytomegalovirus (CMV) serostatus, §myeloablative conditioning, jjcomorbidity
index, ¶stem cell source, **chronic GVHD, and ††race.
‡‡Due to the significant interaction between high-level HHV-6 reactivation and aGVHD grades III-IV for each mode (P5.04 for overall survival and P5
.05 for nonrelapse mortality), a 4-level composite variable was evaluated in the final models including these factors to illustrate the varying association
depending on whether each factor is present singly or in combination. The reference category for this variable is defined by having neither HHV-6 nor
aGVHD grades III-IV. No effect modification was observed between any level HHV-6 and aGVHD grades II-IV, any level HHV-6 and aGVHD grades III-IV,
or between high-level HHV-6 and aGVHD grades II-IV. Therefore, a composite variable was not required for these models.
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significant (Table 3). Significant interactions were ob-
served between high-level HHV-6 and grades III to IV
overall aGVHD for both overall survival (P5 .04) and
nonrelapse mortality (P 5 .05). Thus, we created
a composite variable for high-level HHV-6 and grades
III to IV aGVHD for use in the mortality models to il-
lustrate the varying degrees of association depending
on whether each factor was present singly or in combi-
nation (Table 3). When they occurred alone, both
high-level HHV-6 and grades III to IV aGVHD
were associated with increased risks of mortality com-
pared to absence of the 2 conditions. Co-occurrence of
high-level HHV-6 and grades III to IV aGVHD was
also associated with increased risk of mortality com-
pared with patients with neither condition; however,
the level of risk was not significantly different from
the risk associated with each condition alone. That
is, among patients with grades III to IV aGVHD, ad-
dition of high-level HHV-6 did not result in a signifi-
cantly increased risk ofmortality, although the numberof patients who experienced both high-level HHV-6
and grades III to IV aGVHD was relatively small
(n 5 13). Inclusion of grade II to IV aGVHD in the
models did not have a large effect on the associations
between HHV-6 and mortality. CMV reactivation
was not associated with risk of subsequent mortality
and did not significantly alter the associations between
HHV-6 reactivation and mortality (data not shown).
Analyses of mortality were also performed excluding
the CBT recipients. Point estimates for the HRs
were similar, but significance was diminished or lost
across most categories (data not shown). Only high-
level HHV-6 remained significantly associated with
nonrelapse mortality (HHV-6 only: HR, 3.13; 95%
CI, 1.22-8.03; P 5 .02).
HHV-6 and the Composite Endpoint
HHV-6 reactivation of any level was associated
with the composite endpoint of any mortality, grades
II to IV aGVHD, or any level of CMV reactivation
(aHR, 1.47; 95% CI, 1.08-2.01; P 5 .015). Other
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HCT CMV seropositivity in the donor or recipient,
type of conditioning regimen, stem cell source, pre-
transplantation lymphopenia, andHLAmatch between
the donor and recipient. High-level HHV-6 appeared
even more strongly associated with this composite out-
come (aHR, 2.02; 95%CI, 1.35-3.01;P\.001). Patient
age, stem cell source, type of conditioning regimen,
HLA match between the donor and recipient, and
pre-HCTpositive serology forHSV remained in the fi-
nal model.DISCUSSION
In this prospective study of 315 HCT recipients,
we found that HHV-6 reactivation was associated
with increased risk of subsequent CMV reactivation,
aGVHD, and mortality. Associations between HHV-
6 and grades II to IV aGVHD, nonrelapse mortality,
and high-level CMV reactivation were strengthened
when high-level HHV-6 was evaluated.
Previous studies have shown an association between
HHV-6 and aGVHD [2,17], of which several have used
multivariable analyses in an attempt to control for
potential confounders [4,6,7]. In the current study, we
also evaluated organ-specific subtypes of aGVHD as
outcomes. Results from these analyses suggest that
HHV-6 may play a role in development of each of the
aGVHD subtypes. It is interesting that the strength
of the association between high-level HHV-6 and
skin aGVHD was lessened when CBT recipients were
removed from the analysis. Most of the 21 CBT recip-
ients (76%) in our study received double CBTs, and
these transplantations have been associatedwith greater
risk of skin aGVHD [18]. This finding, along with the
fact that 76% of the CBT recipients in our study had
high-levelHHV-6 reactivation, would explain these re-
sults. The association of HHV-6 reactivation with skin
aGVHD raises the question of whether HHV-6 might
actually trigger aGVHDor simply cause symptoms and
signs that are then attributed to aGVHD. Others have
demonstrated an association between HHV-6 and
rash during the first month after HCT [19-22], and
HHV-6 is known to cause a rash during primary acqui-
sition [23]. Confirming the role of HHV-6 in aGVHD
and distinguishing rash related toHHV-6 from rash re-
lated to aGVHD is necessary in order to target therapy
appropriately.
Although a causal association betweenHHV-6 and
aGVHD has not been established, certain data support
the biologic plausibility of such a relationship. Specifi-
cally, in vitro and limited clinical data suggest that
HHV-6 infectionorreactivationmaycauseaproinflam-
matory or type I immune response, which may play an
important role in the development of aGVHD. For ex-
ample, a type I immune response polarization has been
observed during HHV-6 infection of T cells in vitro[24], and small studies of HCT recipients have docu-
mented a proinflammatory cytokine response (primar-
ily elevated IL-6 concentrations) associated with
HHV-6 reactivation [25,26]. In parallel, a number of
proinflammatory or type I cytokines (IL-2, sIL-2R,
IL-5, IL-6, IL-10, IFN-gamma, IL-12, and IL-18)
have been associated with aGVHD [27-30]. Although
few studies exploring potential associations between
HHV-6, the immune response, and aGVHD have
been described, data from a small number of patients
with HHV-6 reactivation after HCT have implied
a temporal association between elevated cytokines and
rash or aGVHD[26]. Further in vivo study of the effects
of HHV-6 on the immune system may help elucidate
the pathogenesis of HHV-6–related disease.
Seemingly in contrast to the concept of an HHV-
6-induced proinflammatory response, other in vitro
evidence suggests that HHV-6 reactivation might sup-
press the antiviral immune response, potentially
through suppression of IL-12 production [31-33].
Such suppression of antiviral immune responses could
potentially promote the HHV-6 infection itself, as
well as other viral infections, including CMV. In
solid-organ transplantation recipients, HHV-6 reacti-
vation has been independently associatedwithCMVre-
activation and disease [34,35]; whereas studies
conducted in HCT populations have yielded variable
results. In a study of 21 allogeneic HCT recipients,
HHV-6 reactivation was associated with an absence of
CMV-specific lymphocyte proliferative responses,
and persistence of HHV-6 detection was associated
with need for repeated courses of pre-emptive antiviral
therapy against CMV during the first 6 months after
HCT [36]. In contrast, a study of 68 allogeneic HCT
recipients found that HHV-6 reactivation was associ-
ated with CMV reactivation in univariate analysis but
not multivariable analyses [5]. In addition, detection
of HHV-6 DNA in plasma did not seem to affect
CMV-specific T cell immunity reconstitution as mea-
sured by intracellular cytokine staining. Therefore,
the authors concluded that the severe immunosuppres-
sion that attendsHCT leads toHHV-6 andCMV reac-
tivation but that HHV-6 does not predispose to CMV
reactivation or influence the course of active CMV in-
fection [5]. There have been few published studies
that have investigated the association between HHV-
6 reactivation and CMV reactivation/disease in HCT
recipients. The inconsistent results may be due in part
to the small size of previous studies. Given the HR
that we observed for the association between HHV-6
andCMVreactivation, relatively large studies involving
several hundred patients, such as in our study, are
needed to address this question. Despite having a large
study, we did not have an adequate number of patients
with HHV-6 and subsequent receipt of ganciclovir or
foscarnet to assess the impact of these antivirals on
HHV-6 levels and/or on CMV reactivation. A trial
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HHV-6 and CMV reactivation would likely clarify
these issues.
In the present study, we also found that HHV-6
reactivation was independently associated with non-
relapse mortality, and borderline associations were
noted between any-level and high-level HHV-6 reac-
tivation and all-cause mortality. The association be-
tween HHV-6 reactivation and mortality in HCT
has been reported previously in only a few studies
[4,6]. Our data suggest that the association between
HHV-6 andmortality may bemediated partly through
aGVHD. Many complex pathways could link HHV-6
reactivation with increased risk of CMV reactivation,
aGVHD, and mortality. It is also possible that other
clinical conditions, such as central nervous system dis-
ease, pneumonitis, or bone marrow suppression might
mediate the relationship between HHV-6 and mortal-
ity. The experimental design offered by a randomized
controlled trial would likely shed light on these rela-
tionships. Our results also suggest that CBT recipients
were important in driving the statistical significance of
the associations we observed between HHV-6 and
mortality. Thus, CBT recipients may be an important
group to target for future intervention studies.
This study had many strengths, including the size
of the cohort, the frequency and regularity of HHV-
6 testing, and the systematic collection of outcome
data. This allowed us to address important questions
regarding the possible association of HHV-6 reactiva-
tion with CMV reactivation, GVHD, or mortality
more definitively than previous smaller studies. How-
ever, due to the observational study design, we cannot
conclude that HHV-6 reactivation is causally related
to these clinical outcomes. The ubiquitous and persis-
tent nature of HHV-6 infection poses significant chal-
lenges in establishing causal associations between viral
reactivation and disease, especially in immunocompro-
mised populations with multiple complex medical
problems. An antiviral intervention trial would provide
the experimental data required to determine causality.
In summary, we demonstrated an independent and
quantitative association between HHV-6 reactivation
and the outcomes of CMV reactivation, aGVHD,
andmortality. A randomized antiviral trial is warranted
to determine if reducing HHV-6 reactivation will
reduce the incidence of these outcomes after HCT.ACKNOWLEDGMENTS
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